Eiger BioPharmaceuticals Inc expected to post a loss of $7.50 a share - Earnings Preview

Eiger Biopharmaceuticals

22/03/2024 20:26

* Eiger BioPharmaceuticals Inc  EIGR.OQ   EIGR.O  is
expected
to show a rise in quarterly revenue when it reports  results on
March 25 (estimated) for the period ending December 31 2023
    * The Palo Alto California-based  company is expected to
report a
140.3% increase in revenue to $6.479 million from $2.7 million a
year ago, according to the estimate from one analyst, based on
LSEG data.
    * ​LSEG's mean analyst estimate for Eiger BioPharmaceuticals
Inc
is for a loss of $7.50 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Eiger
BioPharmaceuticals Inc is $90.00​, above​ its last closing price
of $5.96. ​​​

This summary was machine generated March 22 at 20:26 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)